Dr Dreyling on Frontline BTK Inhibitor–Based Treatment in Mantle Cell Lymphoma

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.